IIIV vs TYRA vs PCOR

For growth investors, Procore Technologies, Inc.

(PCOR) is the stronger pick with 14. 8% revenue growth year-over-year, versus -7. 3% for i3 Verticals, Inc. (IIIV). i3 Verticals, Inc. (IIIV) offers the better valuation at 39. 3x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate i3 Verticals, Inc. (IIIV) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, i3 Verticals, Inc.

is actually cheaper at 19. 5x.

Over the past 5 years, Tyra Biosciences, Inc.

(TYRA) delivered a total return of +30. 0%, compared to -39. 8% for Procore Technologies, Inc. (PCOR). Over 10 years, the gap is even starker: TYRA returned +30. 0% versus PCOR's -39. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tyra Biosciences, Inc.

(TYRA) is the lower-risk stock at 0. 75β versus Procore Technologies, Inc. 's 1. 40β — meaning PCOR is approximately 86% more volatile than TYRA relative to the S&P 500. On balance sheet safety, i3 Verticals, Inc. (IIIV) carries a lower debt/equity ratio of 1% versus 9% for Procore Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Procore Technologies, Inc.

(PCOR) is pulling ahead at 14. 8% versus -7. 3% for i3 Verticals, Inc. (IIIV). On earnings-per-share growth, the picture is similar: Procore Technologies, Inc. grew EPS 6. 9% year-over-year, compared to -87. 9% for i3 Verticals, Inc.. Over a 3-year CAGR, PCOR leads at 22. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

i3 Verticals, Inc.

(IIIV) is the more profitable company, earning 8. 4% net margin versus -7. 6% for Procore Technologies, Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIIV leads at 1. 9% versus -8. 9% for PCOR. At the gross margin level — before operating expenses — PCOR leads at 78. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, i3 Verticals, Inc.

(IIIV) trades at 19. 5x forward P/E versus 29. 3x for Procore Technologies, Inc. — 9. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TYRA: 49. 4% to $50. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Tyra Biosciences, Inc.

(TYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Both have compounded well over 10 years (TYRA: +30. 0%, PCOR: -39. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IIIV (Technology) and TYRA (Healthcare) and PCOR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.